Frontiers in physiology

Fu's under-skin needling may help muscle repair by balancing energy production in rats with long-term nerve pain

Updated

Abstract

Essence

reduced neuropathic pain and muscle damage markers in rats with chronic peripheral nerve injury, with signals of improved mitochondrial homeostasis.

Evidence

This rat study used histology, ultrastructure, gene-expression, and pathway analyses to show less hypersensitivity and muscle atrophy, preserved mitochondrial density and glycogen storage, and changes in PI3K-Akt, MAPK, oxidative phosphorylation, mitophagy, FGFR1, FGFR3, and phosphorylated FOXO3 after treatment.

Caveat

The evidence is preclinical and mechanistic in a rat model, so clinical benefit and causal pathway links in humans are still uncertain.

Simplified

Key numbers

n = 8
Increase in
Number of rats per group in the and + treatment
n = 8
Significant reduction in muscle weight
Number of rats in each group for muscle weight analysis
n = 8
Significant increase in mitochondrial density
Number of rats analyzed for mitochondrial content in muscle

Key figures

FIGURE 9
Muscle anatomy and molecular pathways of and muscle loss in -induced mice with
Highlights how Fu's subcutaneous needling visibly inhibits excessive autophagy signaling to protect muscle mass in nerve injury models
fphys-16-1640735-g009
  • Upper section
    Anatomical locations of , sciatic nerve, , and muscles with Fu's subcutaneous needling site marked by a red asterisk
  • Lower section
    Molecular mechanisms showing CCI-induced mitochondrial dysfunction activating via PINK1-VDAC-LC3 and FOXO3-BNIP3 pathways causing muscle mass loss, while Fu's subcutaneous needling inhibits FOXO3-BNIP3 autophagy pathway to preserve muscle mass
FIGURE 1
Sham vs vs CCI+: muscle mass, pain sensitivity, and muscle structure in rats
Highlights reduced muscle mass and pain sensitivity in CCI rats and partial recovery with FSN treatment
fphys-16-1640735-g001
  • Panel A
    Experimental timeline showing acclimation, CCI induction, FSN treatment period, and assessment days
  • Panel B
    Bar graph of mechanical withdrawal thresholds (grams) with CCI group showing significantly reduced thresholds versus sham, partially reversed by FSN treatment
  • Panel C
    Anatomical schematic highlighting sciatic nerve and three muscles: , , and
  • Panel D
    Photographs of dissected muscles showing visible muscle atrophy in vastus lateralis and gastrocnemius in CCI group, with apparent recovery in CCI+FSN group
  • Panel E
    Bar graphs of relative muscle weight (% muscle/body weight) showing significant reductions in vastus lateralis and gastrocnemius in CCI group, reversed by FSN; biceps femoris shows no significant change
FIGURE 2
Muscle structure and fiber size in sham, , and CCI + rat groups
Highlights FSN's association with larger muscle fiber size and improved muscle structure after nerve injury
fphys-16-1640735-g002
  • Panels A–C
    H&E staining images of , , and muscles showing muscle fiber atrophy and disorganization in CCI compared to sham, with recovery in CCI + FSN
  • Panel D
    Quantitative (CSA) analysis showing significant CSA reduction in vastus lateralis and gastrocnemius muscles in CCI, mitigated by FSN treatment; biceps femoris CSA shows no significant change
FIGURE 3
Sham vs vs CCI+: muscle fiber ultrastructure and related quantitative measures
Highlights mitochondrial damage and accumulation in CCI, with FSN visibly improving mitochondrial density and preservation.
fphys-16-1640735-g003
  • Panels A and B
    Transmission electron microscopy images of muscle fibers at 2500×, 4000×, and 10,000× magnifications showing mitochondrial (M) damage with swelling and vacuolation in CCI, which FSN treatment visibly reduces; autophagosomes (red arrows) accumulate in CCI and decrease with FSN; glycogen storage (yellow highlights) is disrupted in CCI and improved by FSN.
  • Panel C
    Representative images contrasting normal and damaged states, highlighting structural differences.
  • Panel D
    Quantitative analysis showing increased number of autophagosomes per field in CCI, significantly reduced by FSN treatment.
  • Panel E
    Number of mitochondria per field is significantly lower in CCI and restored in the CCI+FSN group.
  • Panel F
    Glycogen particle density is significantly decreased in CCI compared to sham and partially restored by FSN treatment.
FIGURE 4
Gene expression and pathway enrichment in muscle tissues under versus sham conditions
Highlights distinct gene expression and pathway activation patterns across muscle types under nerve injury conditions
fphys-16-1640735-g004
  • Panel A
    Heatmap of gene expression levels across , , and muscles showing red for upregulation and blue for downregulation under CCI and sham conditions
  • Panel B
    Pathway enrichment dot plot for vastus lateralis comparing CCI versus sham highlighting , , and pathways
  • Panel C
    Pathway enrichment dot plot for biceps femoris comparing CCI versus sham showing PI3K–Akt, MAPK, and AMPK signaling pathways
  • Panel D
    Pathway enrichment dot plot for gastrocnemius comparing CCI versus sham showing PI3K–Akt, MAPK, AMPK, and glucagon signaling pathways
1 / 5

Full Text

What this is

  • () was tested in a rat model of () to assess its effects on muscle repair and mitochondrial function.
  • The study focused on how alleviates neuropathic pain, reduces muscle atrophy, and maintains mitochondrial health.
  • Results showed that treatment improved muscle mass and mitochondrial integrity, suggesting its therapeutic potential in neuropathy-related muscle damage.

Essence

  • treatment mitigated muscle atrophy and mitochondrial dysfunction in a rat model of chronic nerve injury. It restored muscle integrity and energy metabolism, indicating its potential for clinical applications in neuropathy.

Key takeaways

  • treatment improved mechanical withdrawal thresholds and muscle mass in rats. The group exhibited significantly lower thresholds compared to the sham group, while treatment partially restored these thresholds.
  • Histological analysis revealed that treatment preserved muscle structure, as indicated by restored cross-sectional area in the vastus lateralis and gastrocnemius muscles compared to the group.
  • enhanced mitochondrial integrity and reduced autophagosome formation. The number of mitochondria and glycogen density were significantly improved in the -treated group compared to the group.

Caveats

  • The study primarily used a rat model, which may limit the direct applicability of findings to human conditions. Further research is needed to validate these results in clinical settings.
  • The effects of on different muscle types were not uniform; the biceps femoris showed limited improvement compared to the vastus lateralis and gastrocnemius, indicating variability in treatment response.

Definitions

  • Chronic constriction injury (CCI): A model of nerve injury used to study neuropathic pain and associated muscle atrophy through mechanical compression of nerves.
  • Fu's subcutaneous needling (FSN): A therapeutic technique involving the insertion of needles into subcutaneous tissue to alleviate pain and promote tissue repair.

Simplified

Funding

Competing interests

No commercial or financial ties reported.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free